Preclinical Studie of General Toxic Properties of Preparations Containing Ultralow Doses of Antibodies to Endogenous Regulators

Карпова, Г. В.; Фомина, Т. И.; Vetoshkina, T. V.; Dubskaya, T. Yu.; Воронова, О. Л.; Timina, E. A.; Abramova, Elena; Ермолаева, Л. А.; Perova, A. V.

doi:10.1007/s10517-010-0760-3

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 The efficacy and safety of the drugs were intensively studied and proved in different experimental models and in clinical studies as well. 3 – 11 …”

Section: Introductionmentioning

confidence: 99%

In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released-active form

Gorbunov¹,

Ertuzun²,

Качаева³

et al. 2015

NDT

View full text Add to dashboard Cite

Experimentally and clinically, it was shown that released-active form of antibodies to S100 protein (RAF of Abs to S100) exerts a wide range of pharmacological activities: anxiolytic, antiasthenic, antiaggressive, stress-protective, antihypoxic, antiischemic, neuroprotective, and nootropic. The purpose of this study was to determine the influence of RAF of Abs to S100 on major neurotransmitter systems (serotoninergic, GABAergic, dopaminergic, and on sigma receptors as well) which are possibly involved in its mechanism of pharmacological activity. Radioligand binding assays were used for assessment of the drug influence on ligand–receptor interaction. [35S]GTPγS binding assay, cyclic adenosine monophosphate HTRF™, cellular dielectric spectroscopy assays, and assays based on measurement of intracellular concentration of Ca2+ ions were used for assessment of agonist or antagonist properties of the drug toward receptors. RAF of Abs to S100 increased radioligand binding to 5-HT1F, 5-HT2B, 5-HT2Cedited, 5-HT3, and to D3 receptors by 142.0%, 131.9%, 149.3%, 120.7%, and 126.3%, respectively. Also, the drug significantly inhibited specific binding of radioligands to GABAB1A/B2 receptors by 25.8%, and to both native and recombinant human sigma1 receptors by 75.3% and 40.32%, respectively. In the functional assays, it was shown that the drug exerted antagonism at 5-HT1B, D3, and GABAB1A/B2 receptors inhibiting agonist-induced responses by 23.24%, 32.76%, and 30.2%, respectively. On the contrary, the drug exerted an agonist effect at 5-HT1A receptors enhancing receptor functional activity by 28.0%. The pharmacological profiling of RAF of Abs to S100 among 27 receptor provides evidence for drug-related modification of major neurotransmitter systems.

show abstract

“…2 The efficacy and safety of the drugs were intensively studied and proved in different experimental models and in clinical studies as well. 3 – 11 …”

Section: Introductionmentioning

confidence: 99%

In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released-active form

Gorbunov¹,

Ertuzun²,

Качаева³

et al. 2015

NDT

View full text Add to dashboard Cite

show abstract

“…The drugs of this class containing the so-called release-active dilutions of antibodies [3] demonstrated a fundamentally new pro-antigen (cotargeted with antigen) targeted activity, based on the ability of release-active dilutions of antibodies to modify the nature of antigen-target (molecule-target) interaction via the mechanism of conformational modification. The efficacy and safety of the drugs were intensively studied and proved in different experimental models and in clinical studies as well [1, 4–18]. …”

Section: Introductionmentioning

confidence: 99%

The Novel Oral Drug Subetta Exerts an Antidiabetic Effect in the Diabetic Goto-Kakizaki Rat: Comparison with Rosiglitazone

Bailbé

Philippe

Gorbunov³

et al. 2013

Journal of Diabetes Research

View full text Add to dashboard Cite

The aim of the present study was to evaluate the potential antidiabetic effects of two-component drug Subetta and its components (release-active dilutions of antibodies to β-subunit insulin receptor (RAD of Abs to β-InsR) and to endothelial nitric oxide synthase (RAD of Abs to eNOS)) in Goto-Kakizaki (Paris colony) (GK/Par) diabetic rats. Subetta was administered orally for 28 days once daily (5 mL/kg) and compared to its two components (2.5 mL/kg), Rosiglitazone (5 mg/kg), and vehicle (5 mL water/kg). At day 28, fasting plasma glucose levels were significantly decreased only in Subetta and Rosiglitazone groups as compared to vehicle (P < 0.01): 147 ± 4 mg/dL and 145 ± 4 mg/dL and 165 ± 4 mg/dL, respectively. The data of glucose tolerance test showed that Subetta and RAD of Abs to β-InsR (similar to Rosiglitazone) prevented significantly (P < 0.01) the age-related spontaneous deterioration of glucose tolerance as seen in the control group. Subetta and RAD of Abs to β-InsR did not significantly modify the glucose-induced insulin secretion. Chronic administration of Subetta and RAD of Abs to β-InsR improves glucose control, to an extent similar to that of Rosiglitazone. We hypothesize that Subetta and RAD of Abs to β-InsR mostly act via an insulin-sensitizing effect upon target tissues.

show abstract

Release-Activity: A Long Way from Phenomenon to New Drugs

Epstein

2012

Bull Exp Biol Med

View full text Add to dashboard Cite

Multiple dilutions of the original substance release its peculiar activity referred to as "release-activity". Although this activity originates from the initial substance, it does not depend on its negligible concentration in extreme dilutions. Thus, the terms "dose", "ultralow dose", and "homeopathic dose", do not correctly describe the release-active solutions, since the concept of dose implies the presence of some part of the original substance in a dilution with its intrinsic therapeutic potency. The data are reported on the molecular and cellular mechanisms of the mode of action of the release-active agents, some of which being introduced into clinical practice.

show abstract

Preclinical Studie of General Toxic Properties of Preparations Containing Ultralow Doses of Antibodies to Endogenous Regulators

Cited by 5 publications

References 0 publications

In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released-active form

In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released-active form

The Novel Oral Drug Subetta Exerts an Antidiabetic Effect in the Diabetic Goto-Kakizaki Rat: Comparison with Rosiglitazone

Release-Activity: A Long Way from Phenomenon to New Drugs

Contact Info

Product

Resources

About